|
 
- 现金
- 81 元
- 精华
- 0
- 帖子
- 31
- 注册时间
- 2015-1-5
- 最后登录
- 2015-4-21
|
原文：A Matter of Compensation: HCV and Cirrhosis （发表于2015年2月）
图表数据采集自原文：
A study conducted by Bourliere and colleagues included 154 cirrhotic patients with genotype 1 disease who had previously failed pegylated interferon-containing regimens. Seventy-seven patients treated with an all-oral formulation of ledipasvir/sofosbuvir (Harvoni, Gilead) plus ribavirin for 12 weeks reached an SVR12 rate of 96%. The SVR12 rate for 77 patients treated with just ledipasvir/sofosbuvir for 24 weeks was 97%.
Other novel DAA regimens are showing similar results in compensated cirrhotics. Fried and colleagues found that ritonavir-boosted triple therapy with paritaprevir, ombitasvir and dasabuvir (Viekira Pak, AbbVie), known as the “3D” regimen, plus ribavirin yielded a 91.6% SVR12 rate among cirrhotics with genotype 1a disease. The SVR12 rate for the genotype 1b cohort treated with this regimen was 99.2%. The researchers added, however, that genotype 1a disease, along with prior null response to PEG-IFN and ribavirin and IL28B TT genotype, was associated with poorer outcomes.
|
|
发表于 2015-4-17 16:27
